Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the U.K. government that was revealed at the International Investment Summit. The global pharmaceutical giant is set to invest in a new Gateway Lab in the U.
UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...
An Imperial expert in the use artificial intelligence in healthcare has been appointed to the German Ethics Council.
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the ...
Virax Biolabs partners with Europa Biosite to distribute ImmuneSelect for research use, focusing on T-cell immunity and post-viral syndromes, including Long COVID.
From new feedback opportunities to shape the future of the National Health Service in England, to multiple changes and ...
today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR ...
The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...
HG Innovation, the operator of the Elfbar and Lost Mary brands, has announced the formation of an advisory board to provide ...
In the UK, ELFBAR and LOST MARY have been advocating for a more robust approach to vape retailing alongside an enhanced regulatory environment, including a retail licensing scheme for vape products, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback